

Resource Summary Report

Generated by [RRID](#) on Sep 7, 2026

Recombinant Anti-Calreticulin antibody [EPR3924] - ER Marker (Alexa Fluor® 647)

RRID:AB_2819061

Type: Antibody

Proper Citation

Abcam Cat# ab196159, RRID:AB_2819061

Antibody Information

URL: http://antibodyregistry.org/AB_2819061

Proper Citation: Abcam Cat# ab196159, RRID:AB_2819061

Target Antigen: Calreticulin

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: Flow Cyt, ICC/IF

Antibody Name: Recombinant Anti-Calreticulin antibody [EPR3924] - ER Marker (Alexa Fluor® 647)

Description: This monoclonal targets Calreticulin

Target Organism: rat, mouse, human

Clone ID: EPR3924

Antibody ID: AB_2819061

Vendor: Abcam

Catalog Number: ab196159

Record Creation Time: 20231110T032545+0000

Record Last Update: 20260829T163257+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-Calreticulin antibody [EPR3924] - ER Marker (Alexa Fluor® 647).

No alerts have been found for Recombinant Anti-Calreticulin antibody [EPR3924] - ER Marker (Alexa Fluor® 647).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Chen Q, et al. (2026) Identification of an STING inhibitor targeting the allosteric transmembrane domains. Cell chemical biology, 33(5), 623.

Lai Y, et al. (2025) BCG-trained macrophages couple LDLR upregulation to type I IFN responses and antiviral immunity. Cell reports, 44(4), 115493.

Gui L, et al. (2025) Targeting the mevalonate pathway potentiates NUAK1 inhibition-induced immunogenic cell death and antitumor immunity. Cell reports. Medicine, 6(2), 101913.

Rodems TS, et al. (2022) Reversible epigenetic alterations regulate class I HLA loss in prostate cancer. Communications biology, 5(1), 897.

McGrail DJ, et al. (2020) Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer. Cancer cell, 37(3), 371.